Sign In

Login

Password

Forgot Password ? Sign Up

Palbocyklib (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Palbocyklib" in Polish language version.

refsWebsite
Global rank Polish rank
17doi.org
2nd place
6th place
17nih.gov
4th place
7th place
1web.archive.org
1st place
1st place
1europa.eu
68th place
31st place

doi.org

  • A.C. Garrido-Castro, S. Goel. CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. „Curr Breast Cancer Rep”. 9 (1), s. 26–33, 2017. DOI: 10.1007/s12609-017-0232-0. PMID: 28479958. 
  • E.S. Knudsen, A.K. Witkiewicz. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. „Trends Cancer”. 3 (1), s. 39–55, 2017. DOI: 10.1016/j.trecan.2016.11.006. PMID: 28303264. 
  • K.A. Cadoo, A. Gucalp, T.A. Traina. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. „Breast Cancer (Dove Med Press)”. 6, s. 123–133, 2014. DOI: 10.2147/BCTT.S46725. PMID: 25177151. 
  • J. Ettl, N. Harbeck. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. „Expert Rev Anticancer Ther”. 17 (8), s. 661–668, 2017. DOI: 10.1080/14737140.2017.1347506. PMID: 28649895. 
  • M. Preusser, L. De Mattos-Arruda, M. Thill, C. Criscitiello i inni. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. „ESMO Open”. 3 (5), 2018. DOI: 10.1136/esmoopen-2018-000368. PMID: 30167331. 
  • S.C. Scott, S.S. Lee, J. Abraham. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer. „Semin Oncol”. 44 (6), s. 385–394, 2017. DOI: 10.1053/j.seminoncol.2018.01.006. PMID: 29935900. 
  • S.P. Corona, D. Generali. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. „Drug Des Devel Ther”. 12, s. 321–330, 2018. DOI: 10.2147/DDDT.S137783. PMID: 29497278. 
  • D.C. Koboldt, R.S. Fulton, M.D. McLellan, H. Schmidt i inni. Comprehensive molecular portraits of human breast tumours. „Nature”. 490 (7418), s. 61–70, 2012. DOI: 10.1038/nature11412. PMID: 23000897. 
  • S. Pernas, S.M. Tolaney, E.P. Winer, S. Goel. CDK4/6 inhibition in breast cancer: current practice and future directions. „Ther Adv Med Oncol”. 10, s. 1758835918786451, 2018. DOI: 10.1177/1758835918786451. PMID: 30038670. 
  • M. Liu, H. Liu, J. Chen. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review). „Oncol Rep”. 39 (3), s. 901–911, 2018. DOI: 10.3892/or.2018.6221. PMID: 29399694. 
  • A. De Luca, M.R. Maiello, A. D’Alessio, D. Frezzetti i inni. Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. „Expert Opin Drug Metab Toxicol”. 14 (9), s. 891–900, 2018. DOI: 10.1080/17425255.2018.1514720. PMID: 30130984. 
  • E.M. de Dueñas, J. Gavila-Gregori, S. Olmos-Antón, A. Santaballa-Bertrán i inni. Preclinical and clinical development of palbociclib and future perspectives. „Clin Transl Oncol”. 20 (9), s. 1136–1144, 2018. DOI: 10.1007/s12094-018-1850-3. PMID: 29564714. 
  • T.M. McShane, T.A. Wolfe, J.C. Ryan. Updates on managing advanced breast cancer with palbociclib combination therapy. „Ther Adv Med Oncol”. 10, s. 1758835918793849, 2018. DOI: 10.1177/1758835918793849. PMID: 30202448. 
  • E.S. Kim, L.J. Scott. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. „Target Oncol”. 12 (3), s. 373–383, 2017. DOI: 10.1007/s11523-017-0492-7. PMID: 28488183. 
  • R.S. Finn, M. Martin, H.S. Rugo, S. Jones i inni. Palbociclib and Letrozole in Advanced Breast Cancer. „N Engl J Med”. 375 (20), s. 1925–1936, 2016. DOI: 10.1056/NEJMoa1607303. PMID: 27959613. 
  • N.C. Turner, J. Ro, F. André, S. Loi i inni. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. „N Engl J Med”. 373 (3), s. 209–219, 2015. DOI: 10.1056/NEJMoa1505270. PMID: 26030518. 
  • M. Cristofanilli, N.C. Turner, I. Bondarenko, J. Ro i inni. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. „Lancet Oncol”. 17 (4), s. 425–439, 2016. DOI: 10.1016/S1470-2045(15)00613-0. PMID: 26947331. 

europa.eu

ec.europa.eu

  • Urząd Rejestracji Produktów Leczniczych, Charakterystyka produktu leczniczego [dostęp 2018-10-19] [zarchiwizowane z adresu 2018-10-19].

nih.gov

ncbi.nlm.nih.gov

  • A.C. Garrido-Castro, S. Goel. CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. „Curr Breast Cancer Rep”. 9 (1), s. 26–33, 2017. DOI: 10.1007/s12609-017-0232-0. PMID: 28479958. 
  • E.S. Knudsen, A.K. Witkiewicz. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. „Trends Cancer”. 3 (1), s. 39–55, 2017. DOI: 10.1016/j.trecan.2016.11.006. PMID: 28303264. 
  • K.A. Cadoo, A. Gucalp, T.A. Traina. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. „Breast Cancer (Dove Med Press)”. 6, s. 123–133, 2014. DOI: 10.2147/BCTT.S46725. PMID: 25177151. 
  • J. Ettl, N. Harbeck. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. „Expert Rev Anticancer Ther”. 17 (8), s. 661–668, 2017. DOI: 10.1080/14737140.2017.1347506. PMID: 28649895. 
  • M. Preusser, L. De Mattos-Arruda, M. Thill, C. Criscitiello i inni. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. „ESMO Open”. 3 (5), 2018. DOI: 10.1136/esmoopen-2018-000368. PMID: 30167331. 
  • S.C. Scott, S.S. Lee, J. Abraham. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer. „Semin Oncol”. 44 (6), s. 385–394, 2017. DOI: 10.1053/j.seminoncol.2018.01.006. PMID: 29935900. 
  • S.P. Corona, D. Generali. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. „Drug Des Devel Ther”. 12, s. 321–330, 2018. DOI: 10.2147/DDDT.S137783. PMID: 29497278. 
  • D.C. Koboldt, R.S. Fulton, M.D. McLellan, H. Schmidt i inni. Comprehensive molecular portraits of human breast tumours. „Nature”. 490 (7418), s. 61–70, 2012. DOI: 10.1038/nature11412. PMID: 23000897. 
  • S. Pernas, S.M. Tolaney, E.P. Winer, S. Goel. CDK4/6 inhibition in breast cancer: current practice and future directions. „Ther Adv Med Oncol”. 10, s. 1758835918786451, 2018. DOI: 10.1177/1758835918786451. PMID: 30038670. 
  • M. Liu, H. Liu, J. Chen. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review). „Oncol Rep”. 39 (3), s. 901–911, 2018. DOI: 10.3892/or.2018.6221. PMID: 29399694. 
  • A. De Luca, M.R. Maiello, A. D’Alessio, D. Frezzetti i inni. Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. „Expert Opin Drug Metab Toxicol”. 14 (9), s. 891–900, 2018. DOI: 10.1080/17425255.2018.1514720. PMID: 30130984. 
  • E.M. de Dueñas, J. Gavila-Gregori, S. Olmos-Antón, A. Santaballa-Bertrán i inni. Preclinical and clinical development of palbociclib and future perspectives. „Clin Transl Oncol”. 20 (9), s. 1136–1144, 2018. DOI: 10.1007/s12094-018-1850-3. PMID: 29564714. 
  • T.M. McShane, T.A. Wolfe, J.C. Ryan. Updates on managing advanced breast cancer with palbociclib combination therapy. „Ther Adv Med Oncol”. 10, s. 1758835918793849, 2018. DOI: 10.1177/1758835918793849. PMID: 30202448. 
  • E.S. Kim, L.J. Scott. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. „Target Oncol”. 12 (3), s. 373–383, 2017. DOI: 10.1007/s11523-017-0492-7. PMID: 28488183. 
  • R.S. Finn, M. Martin, H.S. Rugo, S. Jones i inni. Palbociclib and Letrozole in Advanced Breast Cancer. „N Engl J Med”. 375 (20), s. 1925–1936, 2016. DOI: 10.1056/NEJMoa1607303. PMID: 27959613. 
  • N.C. Turner, J. Ro, F. André, S. Loi i inni. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. „N Engl J Med”. 373 (3), s. 209–219, 2015. DOI: 10.1056/NEJMoa1505270. PMID: 26030518. 
  • M. Cristofanilli, N.C. Turner, I. Bondarenko, J. Ro i inni. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. „Lancet Oncol”. 17 (4), s. 425–439, 2016. DOI: 10.1016/S1470-2045(15)00613-0. PMID: 26947331. 

web.archive.org

  • Urząd Rejestracji Produktów Leczniczych, Charakterystyka produktu leczniczego [dostęp 2018-10-19] [zarchiwizowane z adresu 2018-10-19].